Trial Profile

A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 099280 (Primary) ; Ipilimumab (Primary)
Indications Liver cancer; Malignant melanoma; Skin cancer
Focus Adverse reactions
Sponsors Incyte Corporation

Most Recent Events

14 Feb 2025 According to ClinicalTrials.gov, this trial is Terminated as this was a strategic business decision. There were no safety concerns contributing to this decision.
14 Feb 2025 Status changed from active, no longer recruiting to discontinued.
03 Jul 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com